Skip to main content
OpenTrials
Completed

NCT Number: NCT05921370

Silodosin in Retrograde Intrarenal Surgery

Selective alpha-blockers have been used for the treatment of ureteric stones as medical expulsive therapy (MET). Recently they have been successfully used in passive ureteric dilatation before semirigid ureteroscopy. This study enables us to know the role of silodosin in ureteric dilatation to facilitate ureteral access sheath placement in Retrograde Intrarenal Surgery with flexible ureteroscopy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Ahmed Maher

Cairo, Cairo Governorate, 11757, Egypt

About this study

The ureteral access sheaths (UAS) used during Retrograde Intrarenal Surgery (RIRS) were produced for easy access to the upper urinary tract. The main advantages of UAS are providing repetitive access to the ureteral and collecting duct system, decreasing intrarenal pressure, preventing bleeding-related distortion of vision by the acceleration of liquid flow, and eventually contributing toward the protection of the flexible device.

Nevertheless, there might be certain challenges during UAS placement. There are also risks, such as ureteral injury and the occurrence of ureteral stricture in the long term. However, considering the benefit/risk balance, RIRS is routinely performed in many clinics because of the ease provided by UAS.

Some problems might occur during the placement of UAS whose diameters vary between 9.5 and 14 Fr. In cases where UAS cannot be placed, manipulations can be used, such as ureteral balloon dilatation, providing access through a rigid ureteroscope with a guide wire, or dilatation with the inner sheath of the UAS, which may vary depending on the amount of personal experience. Despite such manipulations, if UAS placement is still unsuccessful, it is always more logical to place a double-J stent, enables passive dilatation, and postpone RIRS until the second operation.

This study will examine whether intramural ureteral resistance can be reduced or not and whether UAS placement can be facilitated using silodosin or not.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both sex.
  • Age >18 yrs old.
  • Upper ureteric stones or renal stones < 2 cm.
  • Patients with normal renal anatomy.
  • No history of infectious or inflammatory renal condition.

Exclusion criteria

  • • < 18 years old.
  • Multiple or bilateral stones.
  • Pregnant women.
  • Ureteric strictures.
  • Urinary tract infection.
  • Coagulopathy and uncorrected bleeding disorders.
  • Refusal of the surgery and requiring stent.

Treatment and study plan

Silodosin 8 mg

Drug

This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.

Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.

silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement

Placebo

Drug

This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.

Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.

Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.

Primary outcomes

  1. ureteric access sheath placement

    Time frame: intraoperative immediate diagnosis, at the beginning of surgery.

    to assess the success of ureteric access sheath placement as follows:

    • Direct assessment: A. Success of ureteric access sheath insertion without ureteric dilatation. B. Success of ureteric access sheath insertion with ureteric dilatation. C. Failed ureteric access sheath insertion.

Secondary outcomes

  1. operative time

    Time frame: intraoperative diagnosis during the surgery from beginning of the surgery till the end of the procedure

    time of the procedure will be recorded from the beginning of the diagnostic cystoscopy till placement of the flexible ureteroscopy

  2. Perioperative complication

    Time frame: till 7 days postoperative

    regarding of both intraoperative complications in the form of ureteric mucosal tear, ureteric avulsion, residual stones, postoperative pain, dysuria, hematuria, and fever

  3. Cost analysis

    Time frame: 1 day post operative

    evaluation of the cost in both arms by comparing the price for the medication for 7 days on one arm. and the cost of the supplies needed intraoperative for ureteric dilatation or the need for another surgical session

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of Perioperative Silodosin on Ureteric Dilatation in Retrograde Intrarenal Surgery

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 27, 2023
Registry last updated
Jul 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.